Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20863595 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22332721 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4823617 | 0.86 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4823628 | 0.86 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4827606 | 0.86 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4823614 | 0.86 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4827598 | 0.86 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10995616 | 0.81 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11133547 | 0.81 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11133286 | 0.81 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200253996-A1 | TCTP INHIBITING AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, INFECTIOUS DISEASES, ALLERGIES, INFLAMMATIONS AND/OR ASTHMA | UNIVERSITE PARIS-SUD (FR) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253996-A1 | TCTP INHIBITING AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, INFECTIOUS DISEASES, ALLERGIES, INFLAMMATIONS AND/OR ASTHMA | NR3C1, TSLP, FPR3 | SLC6A2 3339/4885SLC6A4 2672/4885SLC6A3 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.